Member Info for leewill39

I always wondered what was the significance of the 300 pg/ml figure Alistair Smith gave out. It seems to be clear now that any LFT manufacturers using antibodies are struggling to get below this level.

Al is “very happy indeed” and I suspect I know why:)

PointBiopharma have signed another licencing deal today. Still cant believe how little Avacta have spoke about their partnership with Point, after all its the 1st licence deal for the Precision platform!

https://www.pointbiopharma.com/press-releases/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment

January 12th, 2021 – TORONTO, CANADA – POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium–177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer. CanProbe, a joint venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC), developed Lu-DOTATATE as it is being used in 167 neuroendocrine tumor (NET) patients in a 180-patient trial with enrollment completed.

“CanProbe’s NET clinical program has helped many patients in Ontario who previously had no other options for treatment,” says Dr. Joe McCann, Chief Executive Officer of POINT Biopharma. “We are excited to extend access to this treatment by leveraging CanProbe’s intellectual property to seek regulatory approvals, with the goal of helping patients in need around the world.” POINT is currently building a state-of-the-art manufacturing facility in Indianapolis, Indiana, to ensure sufficient production capacity is available for Lu-DOTATATE as well as the other drugs in its pipeline.

“We are looking forward to working with POINT Biopharma on the commercialization of Lu-DOTATATE” says Dr. Luke Brzozowski, President of CanProbe. “We believe POINT is the ideal partner to make this treatment accessible to patients in Ontario and across the globe.” CanProbe is also developing the related diagnostic agent, Gallium – 68 Octreotate (Ga-DOTATATE), with cyclotron-produced Ga-68 using solid target technology.

11-Jan-21 15:41:29 132.00 100,000 Buy* 132.00k

I know Avacta are quiet but so are BBI and Abingdon. They were all over Twitter for months and now deadly silence from both.

Just saying.....

Jon Deeks on Sky News at 8 talking about accuracy of LFT’s. Could be an interesting watch.

That something else I’ve been thinking about, just what are Medusa going to do with this manufacturing capacity their building? I don’t believe for 1 second that it’s for that Protein test they’ve developed.

Yes Avacta had to release an RNS as their was confusion regarding Medusa's RPST test and some people believing it was the Avacta test. To be fair Medusa are being careful not to call their product an antibody test, which it certainly is - that doesn't sit well with me. However, I still think the Medusa tie up could be an extremely smart and profitable move by Avacta. Its a profit sharing agreement so Medusa have obviously seen enough to be putting some serious investment in to get ready for the tests.

Just a reminder what Avacta have said about the rational behind the tie up with Medusa19:

Q13: Can you explain the reasoning behind giving exclusive rights to Medusa for direct to consumer sales, and does this mean that tests will not be sold through other platforms such as Amazon?

The Company has explained the commercial rationale for this arrangement several times. Platforms such as Amazon do not provide customer support and post-market surveillance for diagnostic tests that they sell, meaning that if Avacta partnered with an on-line platform like Amazon it would have to put in place a substantial customer support capability as well as other functions. These essential activities will be provided by Medusa 19 under the distribution agreement and the resources have been put in place in readiness for the launch of the Avacta rapid SARS-CoV-2 antigen test. Medusa 19 is committed to building a global business for the antigen test and potentially for a wide range of home testing products in the future, building on significant experience of establishing successful e-commerce businesses.

Probably going to be shot down for bring up Medusa19 again, but I cant help thinking they have a part to play.

They seem to ramping up the marketing and the language has definitely changed, feels like another test is on the way.

https://www.instagram.com/p/CJ6q3x5p743/

medusa19
In 2021, regular testing will be vital in keeping COVID-19 under control. By implementing mass testing in the workplace you can keep business going and restore a sense of normality.

To find out more about Medusa 19's products solutions, including the Rapid Saliva Protein Test (RSPT) visit www.medusa19.com

Some very chunky buys coming through.

Not surprised was able to dummy sell a boat load on HL throughout most of the day.

I agree I doubt they’ve sold much of that test they’ve produced. What I found interesting though is the mention of non-competing saliva tests.

We know the agreement with Avacta prevents Medusa from selling any other rapid antigen tests for Covid. So either the Avacta saliva test is still on or they are no longer working together.

Definitely worth keeping an eye on developments though:)

total scalable COVID 19 solution*

https://medusa19.com/

Interesting change of wording on Medusa19's website.

Partnering with Rapid Saliva Test manufacturers to bring together a suite of non-competing products to provide a total scalable COVID 19 to rebuilding confidence to the economy and the workplace.....

it just goes to show what a hot area this is and the value of deals that are being done.

For all of those that bang on about how can Avacta be worth 300 million when its loss making with small revenues, just take a look at Kymab's last set of results - £29,400,000 loss for year!
https://find-and-update.company-information.service.gov.uk/company/07027523/filing-history

Links to Avacta as well.

https://avacta.com/about/people/

Mike Owen
Senior Independent Director & Scientific Advisory Board Chairman

Dr Owen was Senior Vice President and global Head of Research of the Biopharmaceuticals R&D Unit at GlaxoSmithKline and was responsible for initiating and rapidly growing GSK’s robust pre-clinical and clinical therapeutic antibody pipeline during the last decade through in-house development as well as through acquisitions such as Domantis. He left GSK in 2010 to establish Kymab which is developing biotherapeutics using its novel transgenic mouse platform. Dr Owen is an immunologist by training who had a highly successful scientific career at Imperial Cancer Research during which he was elected a member of the European Molecular Biology Organisation and a fellow of the Academy of Medical Sciences. Dr Owen is also an independent board member at Zealand Pharma and non-executive director of Ossianix Inc. and Blink Therapeutics. He sits on the scientific advisory board of Kymab and also advises the private equity CRT Pioneer Fund and HS Life Sciences.

Rich, Alistair Smith mentioned that they were looking to sell the Elisa test directly as well as put it through distribution. For all we know the Elisa might have been a big seller already.

Thankfully we should get a 12 month trading update at the end of this month so all will be revealed.

https://www.linkedin.com/posts/dhsc_covid19-activity-6754003953979011072-H1_c/

Yeah Matt Han**** looks very happy taking that test:)

Look O&W you make some valid points about the commercialisation of the Avacta tech and it was an area of concern in my research. But, you have to remember that Avacta only acquired the IP in 2012/13 and it was just that a patent, there were no Affimers. It takes time to dispute an established market like antibodies which have been the standard for 30 years.

Also Avacta have only really had a sales team of note for 3 years
https://avacta.com/avacta-establishes-us-business-development-team/

We are now seeing significant deals being done and its accelerating. Its also really encouraging to see the likes of LG Chem extending the partnership, not once but twice. We also now have the Precision platform, which if the animal data is confirmed in humans can be applied to a whole range of tumour targeted drugs. To be fair to Alistair Smith, he said the deal with Tufts would be transformational for the group and I feel we are staring to see signs of that.

No sorry only just scraped GCSE chemistry:)

I'm just a research hog and have done my due diligence. I think that's the problem, too many covid rainbow chasers who cant be bothered to research the company, especially outside of the covid tests. I would highly recommend watching all the Avacta presentations on YouTube staring with the earliest ones as you can see the huge progress this company has made over recent times:)

Vice versa

Avacta own the therapeutic affimer a d exclusively licence the diagnostics one. It’s actually a really nice set up as it keeps both divisions separate and opens up more licensing opportunities. Added to the fact you have the Tomlinson lab almost acting as an extension to Avacta’s research capacity.

Try doing some research for a change Older and not very wise.

Avacta have programs outside of oncology such as autoimmune and inflammatory diseases with partners. They also have a diagnostics division which recently signed a deal with Astrea Bioseparations for the use of the Affimer platform in affinity purification applications.

Steve Burton, President of Astrea Bioseparations commented:

“Affimer reagents are high-performance proteinaceous ligands that have been engineered for a wide range of applications as superior alternatives to antibody-based ligands. They can be used to selectively bind difficult targets, even where antibodies and aptamers have shown limitations. In combination with our proven Mimetic Ligand® chemical ligand libraries, the Affimer ligand platform significantly expands our capacity to discover, develop and deliver custom affinity adsorbents for purification of biotherapeutics and advanced therapies.”

They can be used to selectively bind difficult targets, even where antibodies and aptamers have shown limitations...…just let that sentence sink in.